It is mutually exclusive with other alterations including SPOP and CHD1 loss of function, indicating that TMPRSS2‐ERG negative prostate cancers progress by different tumorigenic processes or represent different cellular subtypes (Shtivelman et al., 2014; Yamoah et al., 2021; Zhu et al., 2021). Here, SPOP is linked to prostate cancer.